What EMulate Therapeutics does

EMulate Therapeutics is a clinical-stage digital therapeutics company developing and commercializing proprietary ultra-low radio frequency energy (ulRFE®) technology that records electromagnetic signatures of validated therapeutic molecules and delivers them non-invasively through wearable devices, without delivering the molecules themselves. The company is organized around four operating entities targeting distinct therapeutic verticals: Cellsana Therapeutics (oncology, with lead programs in Diffuse Midline Glioma including DIPG and Glioblastoma Multiforme; FDA Humanitarian Device Exemption submitted Q2 2024 and Phase 3 ready), Mensana Therapeutics (mental health, targeting PTSD, depression, anxiety, and addiction; Phase 1 ready), Indolor (drug-free pain management for acute and chronic pain in humans and animals; Phase 1 ready), and Hapbee Technologies (consumer wellness wearable producing sensations such as relaxation and alertness). The underlying technology claims a development cost under $500,000 per treatment and a development timeline under 12 months, contrasting with the billions and multi-year timelines typical of traditional pharmaceutical R&D.

The company is based in Bellevue, Washington, with 11-50 employees, and is privately held. Its revenue mechanics are currently pre-commercial for the core therapeutic platform; the wellness arm (Hapbee) is distributed through an exclusive channel partnership with Gharieni Group across Europe and the Middle East, integrating into premium spa tables, beds, and loungers for luxury hospitality operators in over 120 countries, with a retail program enabling consumer at-home device purchases. Capital is being raised through an equity crowdfunding round on Wefunder (launched October 2025) open to both accredited and non-accredited investors to fund Phase 1 clinical trials across indications and near-term commercialization. No institutional venture capital, private equity, or strategic corporate investors are disclosed in available source data, suggesting a founder-controlled capital structure.

Name

EMulate Therapeutics

Legal name

EMulate Therapeutics, Inc.

Website

https://emulatetx.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

EMulate Therapeutics is a clinical-stage digital therapeutics company that records electromagnetic signatures of therapeutic molecules and delivers them through proprietary ulRFE® wearable devices, targeting oncology, mental health, and pain management through wholly-owned subsidiaries.

Ownership category

akta.pro rank

Product category

Digital Therapeutics / Wearable Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

akta.pro secondary industries

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Radiation Oncology (HLAKAFAC)

Keywords

• Digital therapeutics
• Wearable medical devices
• Bioelectromagnetic therapy
• Electromagnetic therapeutics
• Non-invasive oncology therapy

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Community Investment Funding: EMulate Therapeutics raises capital through Wefunder equity crowdfunding round, allowing both accredited and non-accredited investors to participate in funding its digital therapeutics platform.
2. Enterprise Licensing (Hapbee): Licensing of Hapbee bio-streaming wellness technology to enterprise partners like Gharieni Group for integration into premium spa tables, beds, and loungers. Opens revenue streams through hospitality operators retail program.
3. Wearable Therapeutic Devices: Commercialization of wearable devices targeting oncology, mental health, and pain management indications through subsidiaries Cellsana, Mensana, and Indolor.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

EMulate Therapeutics develops a proprietary ulRFE (ultra-low radio frequency energy) technology platform that records electromagnetic signatures of therapeutic molecules and delivers them non-invasively through wearable devices. The platform targets oncology (diffuse midline glioma, glioblastoma multiforme), mental health (PTSD, depression, anxiety, addiction), and pain management indications, and is commercialized through subsidiaries Cellsana Therapeutics, Mensana Therapeutics, Indolor, and the consumer wellness subsidiary Hapbee Technologies.

Product overview

EMulate Therapeutics operates as a digital therapeutics platform built around its proprietary ulRFE® (ultra-low radio frequency energy) technology, which records electromagnetic signatures of therapeutic molecules and delivers them through wearable devices. The company develops treatments across multiple therapeutic areas through subsidiaries: Cellsana (oncology, targeting diffuse midline glioma and glioblastoma), Mensana (mental health/neurological conditions including PTSD, depression, and anxiety), Indolor (pain management for humans and animals), and Hapbee (consumer wellness wearable for sensations like relaxation and alertness). The platform is designed to be non-invasive, drug-free, and compatible with standard treatment pathways.

Differentiator

Problem solved

Functional benefit

Brands

• Cellsana: Oncology-focused applications powered by EM signature technology.
• Mensana
• Indolor
• Hapbee

Products and services

• ulRFE Technology Platform Proprietary ultra-low radio frequency energy platform that records electromagnetic signatures of therapeutic molecules and delivers them through wearable devices to influence cell behavior and support targeted therapeutic outcomes across oncology, mental health, and pain indications.
• Cellsana Therapeutics Oncology-focused therapeutic subsidiary powered by EM signature technology, targeting diffuse midline glioma (including DIPG) and glioblastoma multiforme with ulRFE-based wearable therapy.
• Mensana Therapeutics Neurological and mental-health therapeutics targeting brain function and cognitive balance, addressing PTSD, depression, anxiety, and addiction through signal-based interventions.
• Indolor Drug-free pain management solutions using targeted electromagnetic field modulation for acute and chronic pain in humans and animals.
• Hapbee Consumer wearable device that emulates specific magnetic fields using proprietary ulRFE technology to produce desired sensations such as happiness, alertness, and relaxation for wellness applications, distributed to enterprises via Gharieni Group and to consumers directly.

Quantifiable outcome

• Paclitaxel ulRFE signal demonstrated extension of survival and inhibition of tumor growth in DIPG animal model

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Gharieni GroupcoreChannel Partner/ Reseller/ Distributor · 3 April 2025Strategic partnership making Gharieni the exclusive distributor of Hapbee's Enterprise Solutions for Spa and Wellness across Europe and the Middle East. The agreement enables Hapbee's bio-streaming wellness technology to be integrated into Gharieni's premium spa tables, beds, and loungers, with Gharieni's established distribution network serving luxury hotels and spas in over 120 countries positioned to scale Hapbee's presence in key luxury wellness markets. The partnership also opens new revenue streams for hospitality operators through Hapbee's retail program, enabling properties to offer consumer versions of the technology for at-home use.
• Hapbee Technologies (Subsidiary)coreStrategic or Co-development PartnerHapbee Technologies, Inc. is a subsidiary of EMulate Therapeutics focused on bioelectromagnetic wellness technology. Hapbee devices use proprietary ulRFE technology to emulate specific magnetic fields producing desired sensations such as happiness, alertness, and relaxation. The partnership with Gharieni Group extends Hapbee's market reach through enterprise wellness solutions integration.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hapbee Technologies: EMulate's own subsidiary and consumer-facing licensee of the ulRFE technology; directly comparable as a wearable EM-field wellness device targeting relaxation, alertness, and mood.
• Fisher Wallace: Sells consumer wearable devices that deliver low-level electromagnetic signals to the brain for depression, anxiety, and insomnia — the closest direct competitor to EMulate's Mensana mental-health approach.
• Novocure: Commercial-stage oncology company using Tumor Treating Fields (an electromagnetic modality) for glioblastoma and other solid tumors; directly comparable as a device-based EM therapy in oncology.
• ElectroCore: Developer of non-invasive vagus nerve stimulation (nVNS) devices targeting neurological and inflammatory conditions; comparable as a wearable, non-pharmacologic neurostimulation therapeutic.
• Cala Health: Maker of Cala Trio, a wearable transcutaneous afferent patterned stimulation (TAPS) therapy device for essential tremor; comparable as a prescription wearable therapeutic device company.
• BEMER Group: Markets PEMF (Pulsed Electromagnetic Field) consumer wellness devices for circulation, sleep, and recovery; comparable as a consumer-focused electromagnetic therapy brand in adjacent wellness positioning.

Broad incumbents

• Akili Interactive: Commercial digital therapeutics company delivering FDA-cleared software-based cognitive therapy (EndeavorRx) for ADHD; comparable as a clinical-stage digital therapeutics competitor focused on brain-related indications.
• Oura: Consumer wearable (smart ring) focused on sleep, readiness, and wellness biomarkers; comparable as a wearable wellness hardware company, though with sensing rather than therapeutic signal delivery.

Emerging players

• Big Health: Digital therapeutics company with FDA-cleared products for insomnia and anxiety (Sleepio, Daylight); comparable as a non-pharmacologic, digital modality competitor to EMulate's mental health franchise.
• Limbic: Digital mental health platform combining AI-driven self-help with therapist oversight; comparable as a non-pharmacologic competitor targeting the same mental health indications (anxiety, depression) that EMulate's Mensana pursues.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EMulate Therapeutics